Angiogenesis of prostate cancer and antiangiogenic therapy

Journal of Medical Investigation

Volumn 50, Issue 3-4, 2003, Pages 146-153

  Uehara, Hisanori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiogenesis; Antiangiogenic therapy; Metastasis; Prostate cancer

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CYTOTOXICITY; HUMAN; METASTASIS; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PROSTATE CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENIC PROTEINS; DRUG DESIGN; ENDOSTATINS; HUMANS; INTERFERONS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0346250008     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Landis SH, Murray T, Bolden Wingo PA: Cancer statics 1999. Cancer 49:8-31, 1999
2. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7:254-7, 2000
3. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 157 2212-2218, 1997
4. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res 50:6130-6138, 1990
5. Paget S: The distribution of secondary growth in cancer of the breast. Lancet 1:571-573, 1889
6. Fidler IJ: Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst 87:1588-1592, 1995
7. Folkman MJ: The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71, 1992
8. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 63:265-311, 1994
9. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203-218, 1997
10. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 69:135-174, 1996
11. Dvorak HF: Tumors: wound that do not heal. New Engl J Med 315:1650-1659, 1986
12. Fidler IJ: Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 93:1040-1041, 2001
13. Folkman J: Clinical application of research on angiogenesis. New Engl J Med 333:1753-1763, 1995
14. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
15. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169-180, 1995
16. Campbell SC: Advances in angiogenesis research: relevance to urological oncology. J Urol 158:1663-1674, 1997
17. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW: CD 34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160:459-465, 1998
18. Gospodarowicz D, Abraham JA, Schilling J: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 86:7311-7315, 1989
19. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989
20. Waltenberger J, Claesson Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt 1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994
21. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
22. Terman BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun, 187:1579-1586, 1992
23. Jackson MW, Bentel JM, Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157:2323-2328, 1997
24. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74:910-916, 1996
25. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329-2333, 1997
26. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A: Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139:4672-4678, 1998
27. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA: Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308, 2000
28. Kirschenbaum A, Wang JP, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC: Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncol 3:3-10, 1997
29. Melnyk O, Zimmerman M, Kim KJ, Shuman M: Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161:960-963, 1999
30. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999
31. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898-3911, 1997
32. Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T: Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 80:309-313, 1999
33. Herbert CA, Baker JB: Interleukin-8: a review. Cancer invest 11:743-750, 1993
34. Fidler IJ: Critical determinants of human colon cancer metastasis. In: Tahara E ed. Molecular pathology of gastrointestinal cancer: Application to clinical practice. Springer-Verlag, Tokyo, 1997, pp.147-169
35. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54:3242-3247, 1994
36. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ: Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Patho 1150:1571-1582, 1997
37. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161-167, 1998
38. Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler IJ: Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3:33-42, 2001
39. Mukaida N, Okamoto S, Ishikawa Y, Matsushima KJ: Molecular mechanism of interleukin-8 gene expression. Leukoc Biol 56:554-558, 1994
40. Villarete LH, Remick DG: Transcriptional and post-transcriptional regulation of interleukin-8. Am J Pathol 149:1685-1693, 1996
41. Yokoo T, Kitamura M: Dual regulation of IL-1beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 270:123-130, 1996
42. Bond M, Fabunmi RP, Baker AH, Newby AC: Synergistic upregulation of metalloproteinase-9 (MMP-9) by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435:29-34, 1998
43. Pajonk F, Pajonk K, McBride WH: Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91:1956-1960, 1999
44. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-97, 2001
45. Dow JK, deVere White RW: Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 55:800-806, 2000
46. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Fidler IJ: In situ mRNA hybridization technique for analysis of metastasis-related genes in human prostate carcinoma cells. Am J Patho 1150:1571-1582, 1997
47. Mydlo JH, Michaeli J, Heston WDW, Fair WR: Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 13:297-304, 1988
48. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935, 2000
49. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ: Optimization for the blockade of the epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 7:2563-2572, 2001
50. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP: Antiepidermal growth factor receptor antibody C 225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265, 1999
51. Goldman CK, Kim J, Wong WI, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4:121-133, 1993
52. Schreiber AB, Winkler ME, Derynck R: Trans-forming growth factor-a: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253, 1986
53. Myers RB, Kudlow JE, Grizzle WE: Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol 6:733-737, 1993
54. Glynne-Jones E, Goddard L, Harper ME: Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27:688-694, 1996
55. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, Macoska J A: Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25:199-205, 1994
56. Ross P, Paines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 46:155-159, 1986
57. Schiffer CA: Signal transduction inhibition: changing paradigms in cancer care. Semin Oncol 28:34-39, 2001
58. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F: A role of PDGFR-alpha in basal cell carcinoma proliferation. Proc Natl Acad Sci USA 98:9255-9259, 2001
59. Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G, Heldin CH, Oberg K: Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 50:748-53, 1990
60. Liu YC, Chen SC, Chang C, Leu CM, Hu CP: Platelet-derived growth factor is an autocrine stimulator for the growth and survival of human esophageal carcinoma cell lines. Exp Cell Res 228:206-211, 1996
61. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 93:1266-1274, 1994
62. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67:529-34, 1992
63. Hertzog PJ, Hwang SY, Kola I: Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 39:226-232, 1994
64. Gutterman JU: Cytokine therapeutics: lessons from interferon-alpha. Proc Natl Acad Sci USA 91:1198-1205, 1994
65. Krown SE: Interferons in malignancy: biological products or biological response modifiers? J Natl Cancer Inst 80:306-309, 1988
66. Thomas H, Balkwill FR: Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 52:307-414, 1991
67. Singh RK, Bucana CD, Llansa N, Sanchez R, Fidler IJ: Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int J Oncol 8:649-656, 1996
68. Vermeulen PB, Diriz LY, Martin M, Lemmens J, Van Oosterom AT: Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2 b. J Natl Cancer Inst 89:1316-1317, 1997
69. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ: Interferon-alfa-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-2734, 1999
70. Oliveiera IC, Sciavolino PJ, Lee TH, Vilcek J: Down-regulation of interleukin-8 expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc Natl Acad Sci USA 89:9049-9053, 1992
71. Singh RK, Gutman M, Llansa N, Fidler IJ: Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma. J Interferon Cytokine Res 16:577-584, 1996
72. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 62:5720-5726, 2002
73. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
74. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 60:4362-4365, 2000
75. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241, 1997
76. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X (L). Cell 87:619-628, 1996
77. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470, 2003
78. kip1 and costimulate proliferation of MDA PCa2a and MDA PCa 2 B prostate cancer cells. Clin Cancer Res 5:2171-2177, 1999
79. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8:1253-1264, 2002
80. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M: ZD 1839(Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62:2554-2560, 2002
81. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
82. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ: Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice. Clin Cancer Res 9:1200-1210, 2003
83. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8:2714-2724, 2002